| Detected | Trial | Change |
|---|---|---|
| 2026-08-11 | NCT07573215 Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic… |
Trial sites expanded: 170 -> 210 locations |
| 2026-08-04 | NCT07397338 Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors |
Trial sites expanded: 6 -> 9 locations |
| 2026-08-01 | NCT07252232 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal… |
Trial sites expanded: 43 -> 60 locations |
| 2026-08-01 | NCT07573215 Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic… |
Trial sites expanded: 154 -> 170 locations |
| 2026-07-25 | NCT07573215 Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic… |
Trial sites expanded: 125 -> 154 locations |
| 2026-07-22 | NCT07491445 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With… |
Trial sites expanded: 13 -> 20 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With… | Pancreatic Cancer | Recruiting |
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal… | Pancreatic Cancer | Recruiting |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… | Pancreatic Cancer | Recruiting |
| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | NSCLC (Non-small Cell Lung Cancer) | Recruiting |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic… | Pancreatic Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in… | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Non-Small Cell Lung Cancer, NSCLC | Recruiting |
| NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Colorectal Cancer | Recruiting |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in… | Non-Small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Advanced Solid Tumors | Recruiting |
| Phase 1 | |||
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Recruiting |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With… | Non-Small Cell Lung Cancer (NSCLC) | Active, Not Recruiting |